(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

NCT02561988 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Aggressive Systemic Mastocytosis
Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
Mast Cell Leukemia
Relapsed or Refractory Myeloid Malignancies

Interventions

DRUG: Avapritinib

Sponsor

Blueprint Medicines Corporation